Evidence map›Paper›PMID 25991656›Full record

ArticleThe international journal of neuropsychopharmacology2015

The Role of Serotonin (5-HT) in Behavioral Control: Findings from Animal Research and Clinical Implications.

C L Sanchez, C S Biskup, S Herpertz, T J Gaber, C M Kuhn, S H Hood, F D Zepf

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

C L SanchezClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
C S BiskupClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
S HerpertzClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
T J GaberClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
C M KuhnClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
S H HoodClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF).
F D ZepfClinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany (Drs Sanchez, Biskup, and Mr Gaber); Jülich Aachen Research Alliance, JARA Translational Brain Medicine, Aachen & Jülich, Germany (Drs Sanchez, Biskup, and Mr Gaber); Department of Pharmacology and Cancer Biology, Duke University, Durham, NC (Drs Sanchez and Kuhn); Department of Psychiatry, Psychotherapy and Psychosomatics, University of Heidelberg, Heidelberg, Germany (Dr Herpertz); School of Psychiatry and Clinical Neurosciences (Dr Hood), and Department of Child and Adolescent Psychiatry, School of Psychiatry and Clinical Neurosciences & School of Paediatrics and Child Health (Dr ZEPF), Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA, Australia; Specialised Child and Adolescent Mental Health Services, Department of Health in Western Australia, Perth, WA, Australia (Dr ZEPF) florian.zepf@uwa.edu.au.
Duke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neurotransmitters serotonin and dopamine both have a critical role in the underlying neurobiology of different behaviors. With focus on the interplay between dopamine and serotonin, it has been proposed that dopamine biases behavior towards habitual responding, and with serotonin offsetting this phenomenon and directing the balance toward more flexible, goal-directed responding. The present focus paper stands in close relationship to the publication by Worbe et al. (2015), which deals with the effects of acute tryptophan depletion, a neurodietary physiological method to decrease central nervous serotonin synthesis in humans for a short period of time, on the balance between hypothetical goal-directed and habitual systems. In that research, acute tryptophan depletion challenge administration and a following short-term reduction in central nervous serotonin synthesis were associated with a shift of behavioral performance towards habitual responding, providing further evidence that central nervous serotonin function modulates the balance between goal-directed and stimulus-response habitual systems of behavioral control. In the present focus paper, we discuss the findings by Worbe and colleagues in light of animal experiments as well as clinical implications and discuss potential future avenues for related research.

Indexed as

GoalsHabitsAnimalsExecutive FunctionHumansModels, NeurologicalModels, PsychologicalPsychomotor PerformanceSerotoninSerotoninbehaviordopaminegoal-directed behaviorhabitual respondingSerotonin

Identifiers

PMID25991656
PMCPMC4648158
OpenAlexW1516682569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.